A citation-based method for searching scientific literature

Tao Ouyang, Yanyan Cao, Xuefeng Kan, Lei Chen, Yanqiao Ren, Tao Sun, Liangliang Yan, Bin Xiong, Bin Liang, Chuansheng Zheng. Front Oncol 2021
Times Cited: 3







List of co-cited articles
7 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
66

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Leigh Marcus, Steven J Lemery, Patricia Keegan, Richard Pazdur. Clin Cancer Res 2019
331
66

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Thierry André, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis Punt, Denis Smith, Rocio Garcia-Carbonero, Manuel Benavides, Peter Gibbs,[...]. N Engl J Med 2020
265
66

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
Michael J Overman, Ray McDermott, Joseph L Leach, Sara Lonardi, Heinz-Josef Lenz, Michael A Morse, Jayesh Desai, Andrew Hill, Michael Axelson, Rebecca A Moss,[...]. Lancet Oncol 2017
66

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
Michael J Overman, Sara Lonardi, Ka Yeung Mark Wong, Heinz-Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill,[...]. J Clin Oncol 2018
751
66

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
66

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.
Dung T Le, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert O'Neil, Petr Kavan, Takayuki Yoshino,[...]. J Clin Oncol 2020
211
66

The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs).
Maria P Yavropoulou, Marina Tsoli, Konstantinos Barkas, Gregory Kaltsas, Ashley Grossman. Endocr Relat Cancer 2020
9
33

Incidence of Immune-Mediated Pseudoprogression of Lymphoma Treated with Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis.
Amy Junghyun Lee, Kyung Won Kim, Young Chul Cho, Yousun Ko, Yu Sub Sung, Youngbin Shin, Jiwoo Lee, Mi-Hyun Kim. J Clin Med 2021
1
100

Toxicity of Immunotherapeutic Agents.
Cristina Gutierrez, Colleen McEvoy, Daniel Reynolds, Joseph L Nates. Crit Care Clin 2021
1
100

Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor.
Andrew L Lin, Mark T A Donoghue, Sharon L Wardlaw, T Jonathan Yang, Lisa Bodei, Viviane Tabar, Eliza B Geer. J Clin Endocrinol Metab 2020
7
33

Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells.
Lucy Golden-Mason, Brent E Palmer, Nasim Kassam, Lisa Townshend-Bulson, Stephen Livingston, Brian J McMahon, Nicole Castelblanco, Vijay Kuchroo, David R Gretch, Hugo R Rosen. J Virol 2009
328
33

Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Katsunori Manaka, Junichiro Sato, Maki Takeuchi, Kousuke Watanabe, Hidenori Kage, Taketo Kawai, Yusuke Sato, Takuya Miyagawa, Daisuke Yamada, Haruki Kume,[...]. Sci Rep 2021
1
100

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.
Sydney R Gordon, Roy L Maute, Ben W Dulken, Gregor Hutter, Benson M George, Melissa N McCracken, Rohit Gupta, Jonathan M Tsai, Rahul Sinha, Daniel Corey,[...]. Nature 2017
756
33

The TIGIT/CD226 axis regulates human T cell function.
Ester Lozano, Margarita Dominguez-Villar, Vijay Kuchroo, David A Hafler. J Immunol 2012
215
33

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sander, John M Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J Korman,[...]. J Clin Invest 2015
368
33

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
Haidong Dong, Scott E Strome, Diva R Salomao, Hideto Tamura, Fumiya Hirano, Dallas B Flies, Patrick C Roche, Jun Lu, Gefeng Zhu, Koji Tamada,[...]. Nat Med 2002
33

Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.
Andrew L Lin, Philip Jonsson, Viviane Tabar, T Jonathan Yang, John Cuaron, Katherine Beal, Marc Cohen, Michael Postow, Marc Rosenblum, Jinru Shia,[...]. J Clin Endocrinol Metab 2018
56
33

Analysis of Cyclooxygenase 2, Programmed Cell Death Ligand 1, and Arginase 1 Expression in Human Pituitary Adenoma.
Guodong Zhao, Weike Chen, Juanjuan He, Changmeng Cui, Lihua Zhao, Yueshu Zhao, Cuilian Sun, Dongli Nie, Feng Jin, Lingsheng Kong. World Neurosurg 2020
4
33

Overrepresentation of highly functional T regulatory cells in patients with nonfunctioning pituitary adenoma.
Song Han, Enlong Ma, Wei Jiang, Yu Lu, Xiaoyu Sun, Sizhe Feng. Hum Immunol 2020
1
100

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
Nicholas McGranahan, Andrew J S Furness, Rachel Rosenthal, Sofie Ramskov, Rikke Lyngaa, Sunil Kumar Saini, Mariam Jamal-Hanjani, Gareth A Wilson, Nicolai J Birkbak, Crispin T Hiley,[...]. Science 2016
33

Clinical Insights Into Novel Immune Checkpoint Inhibitors.
Jii Bum Lee, Sang-Jun Ha, Hye Ryun Kim. Front Pharmacol 2021
11
33

Endocrine toxicities of immune checkpoint inhibitors.
Jordan J Wright, Alvin C Powers, Douglas B Johnson. Nat Rev Endocrinol 2021
8
33

Managing side effects of immune checkpoint inhibitors in breast cancer.
Carmen Criscitiello, Chiara Corti, Gabriella Pravettoni, Giuseppe Curigliano. Crit Rev Oncol Hematol 2021
3
33

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.
Loise M Francisco, Victor H Salinas, Keturah E Brown, Vijay K Vanguri, Gordon J Freeman, Vijay K Kuchroo, Arlene H Sharpe. J Exp Med 2009
33

CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction.
P J Blair, J L Riley, B L Levine, K P Lee, N Craighead, T Francomano, S J Perfetto, G S Gray, B M Carreno, C H June. J Immunol 1998
116
33

Hyperbaric Oxygen Boosts PD-1 Antibody Delivery and T Cell Infiltration for Augmented Immune Responses Against Solid Tumors.
Xin Liu, Ningbing Ye, Sha Liu, Jiankun Guan, Qingyuan Deng, Zhijie Zhang, Chen Xiao, Ze-Yang Ding, Bi-Xiang Zhang, Xiao-Ping Chen,[...]. Adv Sci (Weinh) 2021
2
50

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.
Qing Zhang, Jiacheng Bi, Xiaodong Zheng, Yongyan Chen, Hua Wang, Wenyong Wu, Zhengguang Wang, Qiang Wu, Hui Peng, Haiming Wei,[...]. Nat Immunol 2018
350
33

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells.
Xin Yu, Kristin Harden, Lino C Gonzalez, Michelle Francesco, Eugene Chiang, Bryan Irving, Irene Tom, Sinisa Ivelja, Canio J Refino, Hilary Clark,[...]. Nat Immunol 2009
615
33

Research advances on the immune research and prospect of immunotherapy in pituitary adenomas.
Ding Nie, Qiuyue Fang, Bin Li, Jianhua Cheng, Chuzhong Li, Songbai Gui, Yazhuo Zhang, Peng Zhao. World J Surg Oncol 2021
1
100


Pituitary Adenomas: From Diagnosis to Therapeutics.
Samridhi Banskota, David C Adamson. Biomedicines 2021
1
100

Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.
Sofia Lyford-Pike, Shiwen Peng, Geoffrey D Young, Janis M Taube, William H Westra, Belinda Akpeng, Tullia C Bruno, Jeremy D Richmon, Hao Wang, Justin A Bishop,[...]. Cancer Res 2013
510
33

Delayed thrombocytopenia as a rare but serious adverse event secondary to immune checkpoint inhibitor: a case report.
Hui Zhou, Ning Li, Huifeng Tang, Hang Chen, Xiaohui Chen, Liang Zhang, Diehong Tao. Ann Palliat Med 2021
2
50

CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones.
F A Harding, J G McArthur, J A Gross, D H Raulet, J P Allison. Nature 1992
33

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.
Liufu Deng, Hua Liang, Byron Burnette, Michael Beckett, Thomas Darga, Ralph R Weichselbaum, Yang-Xin Fu. J Clin Invest 2014
33

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.
Yu Mei, Wenya Linda Bi, Noah F Greenwald, Ziming Du, Nathalie Y R Agar, Ursula B Kaiser, Whitney W Woodmansee, David A Reardon, Gordon J Freeman, Peter E Fecci,[...]. Oncotarget 2016
63
33

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
33

Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas.
Wenjianlong Zhou, Chuanbao Zhang, Dainan Zhang, Jiayi Peng, Shunchang Ma, Xi Wang, Xiudong Guan, Peiliang Li, Deling Li, Guijun Jia,[...]. J Neurooncol 2020
5
33


[Endocrinopathies induced by immune checkpoint inhibitors].
Jaafar Jaafar, Maria Mavromati, Jacques Philippe. Rev Med Suisse 2018
1
100

Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle.
Antonio Marchetti, Alessia Di Lorito, Fiamma Buttitta. J Thorac Dis 2017
10
33

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
Kaori Sakuishi, Lionel Apetoh, Jenna M Sullivan, Bruce R Blazar, Vijay K Kuchroo, Ana C Anderson. J Exp Med 2010
33

Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions.
Jacqueline Trouillas, Marie-Lise Jaffrain-Rea, Alexandre Vasiljevic, Olaf Dekkers, Vera Popovic, Anne Wierinckx, Ann McCormack, Stephan Petersenn, Pia Burman, Gérald Raverot,[...]. Rev Endocr Metab Disord 2020
4
33

Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223).
Susanne Andreae, Fabienne Piras, Nicolas Burdin, Frédéric Triebel. J Immunol 2002
101
33

LAG3 (CD223) as a cancer immunotherapy target.
Lawrence P Andrews, Ariel E Marciscano, Charles G Drake, Dario A A Vignali. Immunol Rev 2017
320
33

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Shuang Qin, Linping Xu, Ming Yi, Shengnan Yu, Kongming Wu, Suxia Luo. Mol Cancer 2019
255
33

TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.
Xin Gao, Yibei Zhu, Gang Li, Haitao Huang, Guangbo Zhang, Fengming Wang, Jing Sun, Qianting Yang, Xueguang Zhang, Binfeng Lu. PLoS One 2012
215
33


Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
Suzanne L Topalian, Janis M Taube, Robert A Anders, Drew M Pardoll. Nat Rev Cancer 2016
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.